Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial-Reference-Cited by-同舟云学术

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

Published:2018-08 Issue:8 Volume:29 Page:1748-1754
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Malorni L.^ORCID,Curigliano G.,Minisini A.M.,Cinieri S.,Tondini C.A.,D’Hollander K.,Arpino G.,Bernardo A.,Martignetti A.,Criscitiello C.,Puglisi F.^ORCID,Pestrin M.,Sanna G.,Moretti E.,Risi E.,Biagioni C.,McCartney A.,Boni L.,Buyse M.,Migliaccio I.,Biganzoli L.,Di Leo A.

Funder

Investigator Initiated Reaserch Grant from Pzizer

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/8/1748/25505064/mdy214.pdf

Reference14 articles.

1. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer;Miller;Cancer Discov,2011

2. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer;Thangavel;Endocr Relat Cancer,2011

3. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer;Wardell;Clin Cancer Res,2015